nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—L-Phenylalanine—Melphalan—ovarian cancer	0.697	1	CrCrCtD
Dextroamphetamine—Pseudoephedrine—IL2—ovarian cancer	0.00207	0.883	CrCbGaD
Dextroamphetamine—Decreased appetite—Chlorambucil—ovarian cancer	0.00111	0.00424	CcSEcCtD
Dextroamphetamine—Infection—Melphalan—ovarian cancer	0.00111	0.00423	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.0011	0.00422	CcSEcCtD
Dextroamphetamine—Fatigue—Chlorambucil—ovarian cancer	0.0011	0.00421	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Topotecan—ovarian cancer	0.0011	0.0042	CcSEcCtD
Dextroamphetamine—Angioedema—Vinorelbine—ovarian cancer	0.00109	0.00416	CcSEcCtD
Dextroamphetamine—Tachycardia—Melphalan—ovarian cancer	0.00109	0.00415	CcSEcCtD
Dextroamphetamine—Anorexia—Topotecan—ovarian cancer	0.00109	0.00414	CcSEcCtD
Dextroamphetamine—Viral infection—Doxorubicin—ovarian cancer	0.00108	0.00411	CcSEcCtD
Dextroamphetamine—Anorexia—Melphalan—ovarian cancer	0.00106	0.00406	CcSEcCtD
Dextroamphetamine—Palpitations—Vinorelbine—ovarian cancer	0.00105	0.00403	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.00105	0.00401	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00105	0.00399	CcSEcCtD
Dextroamphetamine—Weight decreased—Paclitaxel—ovarian cancer	0.00104	0.00398	CcSEcCtD
Dextroamphetamine—Dyskinesia—Doxorubicin—ovarian cancer	0.00103	0.00395	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Docetaxel—ovarian cancer	0.00103	0.00394	CcSEcCtD
Dextroamphetamine—Hypertension—Vinorelbine—ovarian cancer	0.00103	0.00393	CcSEcCtD
Dextroamphetamine—Depression—Paclitaxel—ovarian cancer	0.00102	0.00391	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.00102	0.00389	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.00102	0.00388	CcSEcCtD
Dextroamphetamine—Urticaria—Chlorambucil—ovarian cancer	0.00102	0.00388	CcSEcCtD
Dextroamphetamine—Chest pain—Vinorelbine—ovarian cancer	0.00102	0.00388	CcSEcCtD
Dextroamphetamine—Dyspnoea—Topotecan—ovarian cancer	0.00102	0.00388	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.00101	0.00387	CcSEcCtD
Dextroamphetamine—Abdominal pain—Chlorambucil—ovarian cancer	0.00101	0.00386	CcSEcCtD
Dextroamphetamine—Body temperature increased—Chlorambucil—ovarian cancer	0.00101	0.00386	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Paclitaxel—ovarian cancer	0.00101	0.00384	CcSEcCtD
Dextroamphetamine—Dyspepsia—Topotecan—ovarian cancer	0.001	0.00383	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Paclitaxel—ovarian cancer	0.000999	0.00381	CcSEcCtD
Dextroamphetamine—Dyspnoea—Melphalan—ovarian cancer	0.000994	0.00379	CcSEcCtD
Dextroamphetamine—Decreased appetite—Topotecan—ovarian cancer	0.00099	0.00378	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000983	0.00375	CcSEcCtD
Dextroamphetamine—Fatigue—Topotecan—ovarian cancer	0.000982	0.00375	CcSEcCtD
Dextroamphetamine—Dyspepsia—Melphalan—ovarian cancer	0.000981	0.00375	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000974	0.00372	CcSEcCtD
Dextroamphetamine—Constipation—Topotecan—ovarian cancer	0.000974	0.00372	CcSEcCtD
Dextroamphetamine—Decreased appetite—Melphalan—ovarian cancer	0.000969	0.0037	CcSEcCtD
Dextroamphetamine—Infection—Vinorelbine—ovarian cancer	0.000968	0.00369	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000963	0.00367	CcSEcCtD
Dextroamphetamine—Fatigue—Melphalan—ovarian cancer	0.000961	0.00367	CcSEcCtD
Dextroamphetamine—Tachycardia—Vinorelbine—ovarian cancer	0.000951	0.00363	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000942	0.0036	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Topotecan—ovarian cancer	0.000931	0.00355	CcSEcCtD
Dextroamphetamine—Anorexia—Vinorelbine—ovarian cancer	0.000928	0.00354	CcSEcCtD
Dextroamphetamine—Asthenia—Chlorambucil—ovarian cancer	0.000918	0.0035	CcSEcCtD
Dextroamphetamine—Urticaria—Topotecan—ovarian cancer	0.000905	0.00345	CcSEcCtD
Dextroamphetamine—Body temperature increased—Topotecan—ovarian cancer	0.0009	0.00344	CcSEcCtD
Dextroamphetamine—Abdominal pain—Topotecan—ovarian cancer	0.0009	0.00344	CcSEcCtD
Dextroamphetamine—Urticaria—Melphalan—ovarian cancer	0.000886	0.00338	CcSEcCtD
Dextroamphetamine—Weight decreased—Docetaxel—ovarian cancer	0.000883	0.00337	CcSEcCtD
Dextroamphetamine—Diarrhoea—Chlorambucil—ovarian cancer	0.000875	0.00334	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Paclitaxel—ovarian cancer	0.000872	0.00333	CcSEcCtD
Dextroamphetamine—Dyspnoea—Vinorelbine—ovarian cancer	0.000868	0.00332	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.000863	0.0033	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000858	0.00328	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Docetaxel—ovarian cancer	0.000853	0.00326	CcSEcCtD
Dextroamphetamine—Decreased appetite—Vinorelbine—ovarian cancer	0.000847	0.00323	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000841	0.00321	CcSEcCtD
Dextroamphetamine—Fatigue—Vinorelbine—ovarian cancer	0.00084	0.00321	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Topotecan—ovarian cancer	0.000839	0.0032	CcSEcCtD
Dextroamphetamine—Constipation—Vinorelbine—ovarian cancer	0.000833	0.00318	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Melphalan—ovarian cancer	0.000821	0.00314	CcSEcCtD
Dextroamphetamine—Asthenia—Topotecan—ovarian cancer	0.000817	0.00312	CcSEcCtD
Dextroamphetamine—Vomiting—Chlorambucil—ovarian cancer	0.000813	0.0031	CcSEcCtD
Dextroamphetamine—Asthenia—Melphalan—ovarian cancer	0.0008	0.00305	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000797	0.00304	CcSEcCtD
Dextroamphetamine—Tension—Paclitaxel—ovarian cancer	0.000788	0.00301	CcSEcCtD
Dextroamphetamine—Nervousness—Paclitaxel—ovarian cancer	0.00078	0.00298	CcSEcCtD
Dextroamphetamine—Diarrhoea—Topotecan—ovarian cancer	0.000779	0.00297	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000778	0.00297	CcSEcCtD
Dextroamphetamine—Urticaria—Vinorelbine—ovarian cancer	0.000774	0.00295	CcSEcCtD
Dextroamphetamine—Abdominal pain—Vinorelbine—ovarian cancer	0.00077	0.00294	CcSEcCtD
Dextroamphetamine—Body temperature increased—Vinorelbine—ovarian cancer	0.00077	0.00294	CcSEcCtD
Dextroamphetamine—Diarrhoea—Melphalan—ovarian cancer	0.000763	0.00291	CcSEcCtD
Dextroamphetamine—Nausea—Chlorambucil—ovarian cancer	0.00076	0.0029	CcSEcCtD
Dextroamphetamine—Dizziness—Topotecan—ovarian cancer	0.000753	0.00287	CcSEcCtD
Dextroamphetamine—Tremor—Paclitaxel—ovarian cancer	0.000752	0.00287	CcSEcCtD
Dextroamphetamine—Affect lability—Epirubicin—ovarian cancer	0.00075	0.00286	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Docetaxel—ovarian cancer	0.000739	0.00282	CcSEcCtD
Dextroamphetamine—Agitation—Paclitaxel—ovarian cancer	0.000738	0.00282	CcSEcCtD
Dextroamphetamine—Angioedema—Paclitaxel—ovarian cancer	0.000734	0.0028	CcSEcCtD
Dextroamphetamine—Vomiting—Topotecan—ovarian cancer	0.000724	0.00276	CcSEcCtD
Dextroamphetamine—Mood swings—Epirubicin—ovarian cancer	0.000722	0.00276	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.00072	0.00275	CcSEcCtD
Dextroamphetamine—Rash—Topotecan—ovarian cancer	0.000718	0.00274	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000718	0.00274	CcSEcCtD
Dextroamphetamine—Dermatitis—Topotecan—ovarian cancer	0.000717	0.00274	CcSEcCtD
Dextroamphetamine—Headache—Topotecan—ovarian cancer	0.000713	0.00272	CcSEcCtD
Dextroamphetamine—Palpitations—Paclitaxel—ovarian cancer	0.000709	0.00271	CcSEcCtD
Dextroamphetamine—Vomiting—Melphalan—ovarian cancer	0.000709	0.00271	CcSEcCtD
Dextroamphetamine—Rash—Melphalan—ovarian cancer	0.000703	0.00268	CcSEcCtD
Dextroamphetamine—Dermatitis—Melphalan—ovarian cancer	0.000702	0.00268	CcSEcCtD
Dextroamphetamine—Asthenia—Vinorelbine—ovarian cancer	0.000699	0.00267	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Epirubicin—ovarian cancer	0.000696	0.00266	CcSEcCtD
Dextroamphetamine—Convulsion—Paclitaxel—ovarian cancer	0.000696	0.00266	CcSEcCtD
Dextroamphetamine—Affect lability—Doxorubicin—ovarian cancer	0.000694	0.00265	CcSEcCtD
Dextroamphetamine—Hypertension—Paclitaxel—ovarian cancer	0.000693	0.00265	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000686	0.00262	CcSEcCtD
Dextroamphetamine—Chest pain—Paclitaxel—ovarian cancer	0.000683	0.00261	CcSEcCtD
Dextroamphetamine—Anxiety—Paclitaxel—ovarian cancer	0.000681	0.0026	CcSEcCtD
Dextroamphetamine—Nausea—Topotecan—ovarian cancer	0.000676	0.00258	CcSEcCtD
Dextroamphetamine—Dry mouth—Paclitaxel—ovarian cancer	0.000668	0.00255	CcSEcCtD
Dextroamphetamine—Mood swings—Doxorubicin—ovarian cancer	0.000668	0.00255	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vinorelbine—ovarian cancer	0.000666	0.00254	CcSEcCtD
Dextroamphetamine—Nausea—Melphalan—ovarian cancer	0.000662	0.00253	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000655	0.0025	CcSEcCtD
Dextroamphetamine—Infection—Paclitaxel—ovarian cancer	0.000651	0.00248	CcSEcCtD
Dextroamphetamine—Dizziness—Vinorelbine—ovarian cancer	0.000644	0.00246	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000644	0.00246	CcSEcCtD
Dextroamphetamine—Tachycardia—Paclitaxel—ovarian cancer	0.000639	0.00244	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000635	0.00242	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000633	0.00242	CcSEcCtD
Dextroamphetamine—Anorexia—Paclitaxel—ovarian cancer	0.000625	0.00238	CcSEcCtD
Dextroamphetamine—Vomiting—Vinorelbine—ovarian cancer	0.000619	0.00236	CcSEcCtD
Dextroamphetamine—Rash—Vinorelbine—ovarian cancer	0.000614	0.00234	CcSEcCtD
Dextroamphetamine—Dermatitis—Vinorelbine—ovarian cancer	0.000614	0.00234	CcSEcCtD
Dextroamphetamine—Headache—Vinorelbine—ovarian cancer	0.00061	0.00233	CcSEcCtD
Dextroamphetamine—Palpitations—Docetaxel—ovarian cancer	0.000601	0.0023	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000601	0.0023	CcSEcCtD
Dextroamphetamine—Weight decreased—Epirubicin—ovarian cancer	0.000596	0.00227	CcSEcCtD
Dextroamphetamine—Insomnia—Paclitaxel—ovarian cancer	0.000593	0.00226	CcSEcCtD
Dextroamphetamine—Convulsion—Docetaxel—ovarian cancer	0.00059	0.00225	CcSEcCtD
Dextroamphetamine—Hypertension—Docetaxel—ovarian cancer	0.000587	0.00224	CcSEcCtD
Dextroamphetamine—Dyspnoea—Paclitaxel—ovarian cancer	0.000584	0.00223	CcSEcCtD
Dextroamphetamine—Somnolence—Paclitaxel—ovarian cancer	0.000582	0.00222	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000582	0.00222	CcSEcCtD
Dextroamphetamine—Chest pain—Docetaxel—ovarian cancer	0.000579	0.00221	CcSEcCtD
Dextroamphetamine—Nausea—Vinorelbine—ovarian cancer	0.000579	0.00221	CcSEcCtD
Dextroamphetamine—Dyspepsia—Paclitaxel—ovarian cancer	0.000577	0.0022	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Epirubicin—ovarian cancer	0.000571	0.00218	CcSEcCtD
Dextroamphetamine—Decreased appetite—Paclitaxel—ovarian cancer	0.00057	0.00217	CcSEcCtD
Dextroamphetamine—Dry mouth—Docetaxel—ovarian cancer	0.000567	0.00216	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000566	0.00216	CcSEcCtD
Dextroamphetamine—Fatigue—Paclitaxel—ovarian cancer	0.000565	0.00216	CcSEcCtD
Dextroamphetamine—Sweating—Epirubicin—ovarian cancer	0.000563	0.00215	CcSEcCtD
Dextroamphetamine—Constipation—Paclitaxel—ovarian cancer	0.00056	0.00214	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000556	0.00212	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000555	0.00212	CcSEcCtD
Dextroamphetamine—Infection—Docetaxel—ovarian cancer	0.000552	0.00211	CcSEcCtD
Dextroamphetamine—Weight decreased—Doxorubicin—ovarian cancer	0.000551	0.0021	CcSEcCtD
Dextroamphetamine—Tachycardia—Docetaxel—ovarian cancer	0.000542	0.00207	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000539	0.00206	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000536	0.00205	CcSEcCtD
Dextroamphetamine—Anorexia—Docetaxel—ovarian cancer	0.000529	0.00202	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000528	0.00202	CcSEcCtD
Dextroamphetamine—Sweating—Doxorubicin—ovarian cancer	0.000521	0.00199	CcSEcCtD
Dextroamphetamine—Urticaria—Paclitaxel—ovarian cancer	0.00052	0.00199	CcSEcCtD
Dextroamphetamine—Abdominal pain—Paclitaxel—ovarian cancer	0.000518	0.00198	CcSEcCtD
Dextroamphetamine—Body temperature increased—Paclitaxel—ovarian cancer	0.000518	0.00198	CcSEcCtD
Dextroamphetamine—Insomnia—Docetaxel—ovarian cancer	0.000502	0.00192	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Epirubicin—ovarian cancer	0.000498	0.0019	CcSEcCtD
Dextroamphetamine—Dyspnoea—Docetaxel—ovarian cancer	0.000495	0.00189	CcSEcCtD
Dextroamphetamine—Somnolence—Docetaxel—ovarian cancer	0.000494	0.00188	CcSEcCtD
Dextroamphetamine—Dyspepsia—Docetaxel—ovarian cancer	0.000489	0.00187	CcSEcCtD
Dextroamphetamine—Decreased appetite—Docetaxel—ovarian cancer	0.000483	0.00184	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000483	0.00184	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000479	0.00183	CcSEcCtD
Dextroamphetamine—Fatigue—Docetaxel—ovarian cancer	0.000479	0.00183	CcSEcCtD
Dextroamphetamine—Constipation—Docetaxel—ovarian cancer	0.000475	0.00181	CcSEcCtD
Dextroamphetamine—Asthenia—Paclitaxel—ovarian cancer	0.00047	0.00179	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Doxorubicin—ovarian cancer	0.000461	0.00176	CcSEcCtD
Dextroamphetamine—TAAR1—female reproductive system—ovarian cancer	0.000458	0.195	CbGeAlD
Dextroamphetamine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000454	0.00173	CcSEcCtD
Dextroamphetamine—Tension—Epirubicin—ovarian cancer	0.00045	0.00172	CcSEcCtD
Dextroamphetamine—Diarrhoea—Paclitaxel—ovarian cancer	0.000448	0.00171	CcSEcCtD
Dextroamphetamine—Nervousness—Epirubicin—ovarian cancer	0.000446	0.0017	CcSEcCtD
Dextroamphetamine—Abdominal pain—Docetaxel—ovarian cancer	0.000439	0.00168	CcSEcCtD
Dextroamphetamine—Body temperature increased—Docetaxel—ovarian cancer	0.000439	0.00168	CcSEcCtD
Dextroamphetamine—Dizziness—Paclitaxel—ovarian cancer	0.000433	0.00165	CcSEcCtD
Dextroamphetamine—Agitation—Epirubicin—ovarian cancer	0.000422	0.00161	CcSEcCtD
Dextroamphetamine—Tension—Doxorubicin—ovarian cancer	0.000417	0.00159	CcSEcCtD
Dextroamphetamine—Vomiting—Paclitaxel—ovarian cancer	0.000417	0.00159	CcSEcCtD
Dextroamphetamine—Rash—Paclitaxel—ovarian cancer	0.000413	0.00158	CcSEcCtD
Dextroamphetamine—Dermatitis—Paclitaxel—ovarian cancer	0.000413	0.00158	CcSEcCtD
Dextroamphetamine—Nervousness—Doxorubicin—ovarian cancer	0.000412	0.00157	CcSEcCtD
Dextroamphetamine—Headache—Paclitaxel—ovarian cancer	0.00041	0.00157	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Docetaxel—ovarian cancer	0.000409	0.00156	CcSEcCtD
Dextroamphetamine—Palpitations—Epirubicin—ovarian cancer	0.000406	0.00155	CcSEcCtD
Dextroamphetamine—Asthenia—Docetaxel—ovarian cancer	0.000398	0.00152	CcSEcCtD
Dextroamphetamine—Convulsion—Epirubicin—ovarian cancer	0.000398	0.00152	CcSEcCtD
Dextroamphetamine—Hypertension—Epirubicin—ovarian cancer	0.000396	0.00151	CcSEcCtD
Dextroamphetamine—Chest pain—Epirubicin—ovarian cancer	0.000391	0.00149	CcSEcCtD
Dextroamphetamine—Agitation—Doxorubicin—ovarian cancer	0.00039	0.00149	CcSEcCtD
Dextroamphetamine—Anxiety—Epirubicin—ovarian cancer	0.000389	0.00149	CcSEcCtD
Dextroamphetamine—Nausea—Paclitaxel—ovarian cancer	0.000389	0.00149	CcSEcCtD
Dextroamphetamine—Dry mouth—Epirubicin—ovarian cancer	0.000382	0.00146	CcSEcCtD
Dextroamphetamine—Diarrhoea—Docetaxel—ovarian cancer	0.00038	0.00145	CcSEcCtD
Dextroamphetamine—Palpitations—Doxorubicin—ovarian cancer	0.000375	0.00143	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000375	0.00143	CcSEcCtD
Dextroamphetamine—Infection—Epirubicin—ovarian cancer	0.000372	0.00142	CcSEcCtD
Dextroamphetamine—Convulsion—Doxorubicin—ovarian cancer	0.000368	0.0014	CcSEcCtD
Dextroamphetamine—Dizziness—Docetaxel—ovarian cancer	0.000367	0.0014	CcSEcCtD
Dextroamphetamine—Hypertension—Doxorubicin—ovarian cancer	0.000367	0.0014	CcSEcCtD
Dextroamphetamine—Tachycardia—Epirubicin—ovarian cancer	0.000366	0.0014	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000362	0.00138	CcSEcCtD
Dextroamphetamine—Chest pain—Doxorubicin—ovarian cancer	0.000362	0.00138	CcSEcCtD
Dextroamphetamine—Anxiety—Doxorubicin—ovarian cancer	0.00036	0.00138	CcSEcCtD
Dextroamphetamine—Anorexia—Epirubicin—ovarian cancer	0.000357	0.00136	CcSEcCtD
Dextroamphetamine—Dry mouth—Doxorubicin—ovarian cancer	0.000354	0.00135	CcSEcCtD
Dextroamphetamine—Vomiting—Docetaxel—ovarian cancer	0.000353	0.00135	CcSEcCtD
Dextroamphetamine—Rash—Docetaxel—ovarian cancer	0.00035	0.00134	CcSEcCtD
Dextroamphetamine—Dermatitis—Docetaxel—ovarian cancer	0.00035	0.00134	CcSEcCtD
Dextroamphetamine—Headache—Docetaxel—ovarian cancer	0.000348	0.00133	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000347	0.00132	CcSEcCtD
Dextroamphetamine—Infection—Doxorubicin—ovarian cancer	0.000344	0.00131	CcSEcCtD
Dextroamphetamine—Insomnia—Epirubicin—ovarian cancer	0.000339	0.00129	CcSEcCtD
Dextroamphetamine—Tachycardia—Doxorubicin—ovarian cancer	0.000338	0.00129	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000335	0.00128	CcSEcCtD
Dextroamphetamine—Dyspnoea—Epirubicin—ovarian cancer	0.000334	0.00127	CcSEcCtD
Dextroamphetamine—Somnolence—Epirubicin—ovarian cancer	0.000333	0.00127	CcSEcCtD
Dextroamphetamine—Anorexia—Doxorubicin—ovarian cancer	0.00033	0.00126	CcSEcCtD
Dextroamphetamine—Nausea—Docetaxel—ovarian cancer	0.00033	0.00126	CcSEcCtD
Dextroamphetamine—Dyspepsia—Epirubicin—ovarian cancer	0.00033	0.00126	CcSEcCtD
Dextroamphetamine—Decreased appetite—Epirubicin—ovarian cancer	0.000326	0.00124	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000323	0.00123	CcSEcCtD
Dextroamphetamine—Fatigue—Epirubicin—ovarian cancer	0.000323	0.00123	CcSEcCtD
Dextroamphetamine—Constipation—Epirubicin—ovarian cancer	0.00032	0.00122	CcSEcCtD
Dextroamphetamine—Insomnia—Doxorubicin—ovarian cancer	0.000313	0.0012	CcSEcCtD
Dextroamphetamine—Dyspnoea—Doxorubicin—ovarian cancer	0.000309	0.00118	CcSEcCtD
Dextroamphetamine—Somnolence—Doxorubicin—ovarian cancer	0.000308	0.00118	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000306	0.00117	CcSEcCtD
Dextroamphetamine—Dyspepsia—Doxorubicin—ovarian cancer	0.000305	0.00116	CcSEcCtD
Dextroamphetamine—Decreased appetite—Doxorubicin—ovarian cancer	0.000301	0.00115	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000299	0.00114	CcSEcCtD
Dextroamphetamine—Fatigue—Doxorubicin—ovarian cancer	0.000299	0.00114	CcSEcCtD
Dextroamphetamine—Urticaria—Epirubicin—ovarian cancer	0.000298	0.00114	CcSEcCtD
Dextroamphetamine—Constipation—Doxorubicin—ovarian cancer	0.000296	0.00113	CcSEcCtD
Dextroamphetamine—Abdominal pain—Epirubicin—ovarian cancer	0.000296	0.00113	CcSEcCtD
Dextroamphetamine—Body temperature increased—Epirubicin—ovarian cancer	0.000296	0.00113	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000283	0.00108	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Epirubicin—ovarian cancer	0.000276	0.00105	CcSEcCtD
Dextroamphetamine—Selegiline—ABCB1—ovarian cancer	0.000276	0.117	CrCbGaD
Dextroamphetamine—Urticaria—Doxorubicin—ovarian cancer	0.000275	0.00105	CcSEcCtD
Dextroamphetamine—Body temperature increased—Doxorubicin—ovarian cancer	0.000274	0.00105	CcSEcCtD
Dextroamphetamine—Abdominal pain—Doxorubicin—ovarian cancer	0.000274	0.00105	CcSEcCtD
Dextroamphetamine—Asthenia—Epirubicin—ovarian cancer	0.000269	0.00103	CcSEcCtD
Dextroamphetamine—Diarrhoea—Epirubicin—ovarian cancer	0.000256	0.000978	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000255	0.000975	CcSEcCtD
Dextroamphetamine—Asthenia—Doxorubicin—ovarian cancer	0.000249	0.000949	CcSEcCtD
Dextroamphetamine—Dizziness—Epirubicin—ovarian cancer	0.000248	0.000946	CcSEcCtD
Dextroamphetamine—Vomiting—Epirubicin—ovarian cancer	0.000238	0.000909	CcSEcCtD
Dextroamphetamine—Diarrhoea—Doxorubicin—ovarian cancer	0.000237	0.000905	CcSEcCtD
Dextroamphetamine—Rash—Epirubicin—ovarian cancer	0.000236	0.000902	CcSEcCtD
Dextroamphetamine—Dermatitis—Epirubicin—ovarian cancer	0.000236	0.000901	CcSEcCtD
Dextroamphetamine—Headache—Epirubicin—ovarian cancer	0.000235	0.000896	CcSEcCtD
Dextroamphetamine—Dizziness—Doxorubicin—ovarian cancer	0.000229	0.000875	CcSEcCtD
Dextroamphetamine—Nausea—Epirubicin—ovarian cancer	0.000222	0.000849	CcSEcCtD
Dextroamphetamine—Vomiting—Doxorubicin—ovarian cancer	0.00022	0.000841	CcSEcCtD
Dextroamphetamine—Rash—Doxorubicin—ovarian cancer	0.000219	0.000834	CcSEcCtD
Dextroamphetamine—Dermatitis—Doxorubicin—ovarian cancer	0.000218	0.000833	CcSEcCtD
Dextroamphetamine—Headache—Doxorubicin—ovarian cancer	0.000217	0.000829	CcSEcCtD
Dextroamphetamine—SLC18A2—uterine cervix—ovarian cancer	0.000208	0.0884	CbGeAlD
Dextroamphetamine—Nausea—Doxorubicin—ovarian cancer	0.000206	0.000786	CcSEcCtD
Dextroamphetamine—SLC18A2—endometrium—ovarian cancer	0.000188	0.08	CbGeAlD
Dextroamphetamine—SLC18A2—uterus—ovarian cancer	0.000173	0.0737	CbGeAlD
Dextroamphetamine—SLC18A2—female reproductive system—ovarian cancer	0.000156	0.0663	CbGeAlD
Dextroamphetamine—SLC18A2—vagina—ovarian cancer	0.000141	0.0599	CbGeAlD
Dextroamphetamine—SLC18A2—testis—ovarian cancer	0.000126	0.0535	CbGeAlD
Dextroamphetamine—SLC6A2—decidua—ovarian cancer	0.000121	0.0514	CbGeAlD
Dextroamphetamine—ADRA1A—epithelium—ovarian cancer	0.000119	0.0506	CbGeAlD
Dextroamphetamine—SLC6A2—gonad—ovarian cancer	0.000106	0.0453	CbGeAlD
Dextroamphetamine—SLC6A3—testis—ovarian cancer	9.51e-05	0.0404	CbGeAlD
Dextroamphetamine—SLC6A2—female reproductive system—ovarian cancer	9.51e-05	0.0404	CbGeAlD
Dextroamphetamine—SLC18A2—lymph node—ovarian cancer	9.11e-05	0.0388	CbGeAlD
Dextroamphetamine—SLC6A2—testis—ovarian cancer	7.67e-05	0.0326	CbGeAlD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PIK3CD—ovarian cancer	6.93e-05	0.00191	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	6.87e-05	0.0019	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—ovarian cancer	6.78e-05	0.00187	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	6.77e-05	0.00187	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	6.68e-05	0.00184	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	6.51e-05	0.0018	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—PIK3CA—ovarian cancer	6.44e-05	0.00178	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.44e-05	0.00178	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PPP2R1A—ovarian cancer	6.31e-05	0.00174	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—AKT1—ovarian cancer	6.29e-05	0.00174	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PIK3CD—ovarian cancer	6.29e-05	0.00174	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HSD17B6—ovarian cancer	6.24e-05	0.00172	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—ovarian cancer	6.23e-05	0.00172	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.22e-05	0.00172	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PIK3CB—ovarian cancer	6.04e-05	0.00167	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (12/13) signalling events—PIK3CA—ovarian cancer	6.03e-05	0.00166	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DLC1—ovarian cancer	5.97e-05	0.00165	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—AKT1—ovarian cancer	5.92e-05	0.00164	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCL8—ovarian cancer	5.8e-05	0.0016	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	5.78e-05	0.0016	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.7e-05	0.00157	CbGpPWpGaD
Dextroamphetamine—SLC6A2—lymph node—ovarian cancer	5.56e-05	0.0237	CbGeAlD
Dextroamphetamine—TAAR1—GPCR downstream signaling—IL2—ovarian cancer	5.54e-05	0.00153	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—ovarian cancer	5.52e-05	0.00152	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.51e-05	0.00152	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PIK3CB—ovarian cancer	5.48e-05	0.00151	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DLC1—ovarian cancer	5.3e-05	0.00146	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCL8—ovarian cancer	5.27e-05	0.00145	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—MAPK1—ovarian cancer	5.26e-05	0.00145	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—AKT1—ovarian cancer	5.26e-05	0.00145	CbGpPWpGaD
Dextroamphetamine—CYP2D6—female reproductive system—ovarian cancer	5.21e-05	0.0221	CbGeAlD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL2—ovarian cancer	5.03e-05	0.00139	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TERT—ovarian cancer	5.02e-05	0.00139	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.91e-05	0.00136	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BCL9—ovarian cancer	4.87e-05	0.00134	CbGpPWpGaD
Dextroamphetamine—CYP2D6—female gonad—ovarian cancer	4.74e-05	0.0201	CbGeAlD
Dextroamphetamine—TAAR1—Signaling Pathways—CAV1—ovarian cancer	4.64e-05	0.00128	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ESR1—ovarian cancer	4.47e-05	0.00123	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6ST—ovarian cancer	4.4e-05	0.00121	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.35e-05	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BCL9—ovarian cancer	4.32e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—APC—ovarian cancer	4.23e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PIK3CG—ovarian cancer	4.23e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—NRAS—ovarian cancer	4.23e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—HRAS—ovarian cancer	4.23e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—CYP2D6—testis—ovarian cancer	4.2e-05	0.0179	CbGeAlD
Dextroamphetamine—CYP2D6—Metabolism—NME2—ovarian cancer	4.13e-05	0.00114	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.1e-05	0.00113	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—MAPK3—ovarian cancer	4.05e-05	0.00112	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—MAPK1—ovarian cancer	3.85e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—EGFR—ovarian cancer	3.85e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DOK1—ovarian cancer	3.85e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PIK3CD—ovarian cancer	3.72e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	3.69e-05	0.00102	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PIK3CA—ovarian cancer	3.68e-05	0.00102	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—KRAS—ovarian cancer	3.64e-05	0.001	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PPP1CC—ovarian cancer	3.62e-05	0.000999	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	3.54e-05	0.000977	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DOK1—ovarian cancer	3.42e-05	0.000944	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	3.41e-05	0.000942	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	3.37e-05	0.00093	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	3.37e-05	0.000929	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PIK3CA—ovarian cancer	3.34e-05	0.000923	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.29e-05	0.000908	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ERBB2—ovarian cancer	3.28e-05	0.000906	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	3.28e-05	0.000906	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—ovarian cancer	3.27e-05	0.000902	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PIK3CB—ovarian cancer	3.24e-05	0.000894	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MTOR—ovarian cancer	3.24e-05	0.000894	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PPP1CC—ovarian cancer	3.21e-05	0.000887	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	3.18e-05	0.000878	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	3.14e-05	0.000868	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—MAPK1—ovarian cancer	3.14e-05	0.000867	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL8—ovarian cancer	3.11e-05	0.000859	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HRAS—ovarian cancer	3.09e-05	0.000854	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CDKN1B—ovarian cancer	3.04e-05	0.000839	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	3.03e-05	0.000836	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AKT1—ovarian cancer	3.01e-05	0.00083	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	2.99e-05	0.000826	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	2.99e-05	0.000826	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CASP3—ovarian cancer	2.98e-05	0.000823	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL2—ovarian cancer	2.97e-05	0.000821	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—ovarian cancer	2.96e-05	0.000817	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	2.92e-05	0.000807	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—PIK3CA—ovarian cancer	2.9e-05	0.000801	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCND1—ovarian cancer	2.9e-05	0.000801	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CTNNB1—ovarian cancer	2.87e-05	0.000793	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	2.82e-05	0.00078	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MMP9—ovarian cancer	2.81e-05	0.000777	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTEN—ovarian cancer	2.8e-05	0.000773	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HDAC6—ovarian cancer	2.74e-05	0.000757	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AKT1—ovarian cancer	2.73e-05	0.000754	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PPP2R1A—ovarian cancer	2.7e-05	0.000747	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	2.7e-05	0.000746	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYTB—ovarian cancer	2.66e-05	0.000735	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL8—ovarian cancer	2.6e-05	0.000717	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	2.59e-05	0.000717	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	2.59e-05	0.000714	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VEGFA—ovarian cancer	2.53e-05	0.000698	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—HRAS—ovarian cancer	2.52e-05	0.000696	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—STAT3—ovarian cancer	2.5e-05	0.000691	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NRAS—ovarian cancer	2.5e-05	0.000689	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HDAC6—ovarian cancer	2.43e-05	0.000672	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—YAP1—ovarian cancer	2.43e-05	0.00067	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PPP2R1A—ovarian cancer	2.4e-05	0.000663	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	2.4e-05	0.000663	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MAPK3—ovarian cancer	2.39e-05	0.00066	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—XIAP—ovarian cancer	2.38e-05	0.000656	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.33e-05	0.000642	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.33e-05	0.000642	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MYC—ovarian cancer	2.33e-05	0.000642	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SMARCA4—ovarian cancer	2.32e-05	0.00064	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL8—ovarian cancer	2.31e-05	0.000637	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	2.3e-05	0.000635	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MAPK1—ovarian cancer	2.28e-05	0.000628	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EGFR—ovarian cancer	2.27e-05	0.000628	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EREG—ovarian cancer	2.26e-05	0.000624	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—YAP1—ovarian cancer	2.15e-05	0.000595	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KRAS—ovarian cancer	2.15e-05	0.000593	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PGR—ovarian cancer	2.12e-05	0.000585	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—XIAP—ovarian cancer	2.11e-05	0.000583	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SMARCA4—ovarian cancer	2.06e-05	0.000568	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EREG—ovarian cancer	2.01e-05	0.000554	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CG—ovarian cancer	1.99e-05	0.00055	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PIK3CA—ovarian cancer	1.97e-05	0.000545	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PARP1—ovarian cancer	1.97e-05	0.000544	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—ovarian cancer	1.91e-05	0.000527	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6ST—ovarian cancer	1.88e-05	0.00052	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PGR—ovarian cancer	1.88e-05	0.00052	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HRAS—ovarian cancer	1.83e-05	0.000504	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CG—ovarian cancer	1.81e-05	0.0005	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CG—ovarian cancer	1.77e-05	0.000489	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CD—ovarian cancer	1.75e-05	0.000484	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PARP1—ovarian cancer	1.75e-05	0.000483	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—ovarian cancer	1.75e-05	0.000483	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6ST—ovarian cancer	1.67e-05	0.000462	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKT1—ovarian cancer	1.61e-05	0.000445	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CG—ovarian cancer	1.61e-05	0.000444	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PPP2R1A—ovarian cancer	1.6e-05	0.000441	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CD—ovarian cancer	1.59e-05	0.000439	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—YAP1—ovarian cancer	1.56e-05	0.000431	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CD—ovarian cancer	1.56e-05	0.00043	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CB—ovarian cancer	1.53e-05	0.000422	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL8—ovarian cancer	1.47e-05	0.000405	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PPP2R1A—ovarian cancer	1.42e-05	0.000392	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CD—ovarian cancer	1.41e-05	0.00039	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL2—ovarian cancer	1.4e-05	0.000387	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CB—ovarian cancer	1.39e-05	0.000383	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CB—ovarian cancer	1.36e-05	0.000375	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL8—ovarian cancer	1.33e-05	0.000368	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL8—ovarian cancer	1.3e-05	0.00036	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL2—ovarian cancer	1.27e-05	0.000352	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—FASN—ovarian cancer	1.27e-05	0.000351	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TERT—ovarian cancer	1.27e-05	0.00035	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.25e-05	0.000345	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL2—ovarian cancer	1.25e-05	0.000344	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CB—ovarian cancer	1.23e-05	0.00034	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.21e-05	0.000334	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL8—ovarian cancer	1.18e-05	0.000327	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CAV1—ovarian cancer	1.17e-05	0.000324	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.16e-05	0.00032	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2—ovarian cancer	1.13e-05	0.000312	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ESR1—ovarian cancer	1.13e-05	0.000312	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TERT—ovarian cancer	1.13e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6ST—ovarian cancer	1.11e-05	0.000307	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APC—ovarian cancer	1.07e-05	0.000295	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CG—ovarian cancer	1.07e-05	0.000295	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—NRAS—ovarian cancer	1.07e-05	0.000295	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CAV1—ovarian cancer	1.04e-05	0.000288	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.03e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAPK3—ovarian cancer	1.02e-05	0.000283	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ESR1—ovarian cancer	1e-05	0.000277	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6ST—ovarian cancer	9.88e-06	0.000273	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAPK1—ovarian cancer	9.74e-06	0.000269	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EGFR—ovarian cancer	9.74e-06	0.000269	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCB1—ovarian cancer	9.54e-06	0.000263	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APC—ovarian cancer	9.5e-06	0.000262	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CG—ovarian cancer	9.5e-06	0.000262	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—NRAS—ovarian cancer	9.5e-06	0.000262	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CD—ovarian cancer	9.4e-06	0.00026	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TYMS—ovarian cancer	9.37e-06	0.000259	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CA—ovarian cancer	9.31e-06	0.000257	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KRAS—ovarian cancer	9.2e-06	0.000254	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAPK3—ovarian cancer	9.09e-06	0.000251	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	8.65e-06	0.000239	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	8.65e-06	0.000239	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	8.45e-06	0.000233	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	8.35e-06	0.000231	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	8.3e-06	0.000229	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	8.27e-06	0.000228	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	8.19e-06	0.000226	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	8.19e-06	0.000226	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	8.17e-06	0.000226	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	7.87e-06	0.000217	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	7.82e-06	0.000216	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	7.69e-06	0.000212	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	7.6e-06	0.00021	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CAV1—ovarian cancer	7.55e-06	0.000208	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	7.53e-06	0.000208	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2—ovarian cancer	7.52e-06	0.000208	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	7.51e-06	0.000207	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	7.49e-06	0.000207	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	7.37e-06	0.000204	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	7.33e-06	0.000203	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	7.28e-06	0.000201	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	7.28e-06	0.000201	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	7.26e-06	0.000201	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	7.12e-06	0.000197	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	7.08e-06	0.000195	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	6.99e-06	0.000193	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	6.95e-06	0.000192	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	6.91e-06	0.000191	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.88e-06	0.00019	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	6.83e-06	0.000189	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	6.76e-06	0.000187	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	6.69e-06	0.000185	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	6.68e-06	0.000185	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	6.65e-06	0.000184	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	6.51e-06	0.00018	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	6.45e-06	0.000178	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	6.39e-06	0.000177	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	6.33e-06	0.000175	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	6.32e-06	0.000175	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	6.32e-06	0.000174	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	6.29e-06	0.000174	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	6.13e-06	0.000169	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	6.05e-06	0.000167	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	6.04e-06	0.000167	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	5.88e-06	0.000162	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	5.76e-06	0.000159	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	5.75e-06	0.000159	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	5.68e-06	0.000157	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	5.62e-06	0.000155	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	5.61e-06	0.000155	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	5.44e-06	0.00015	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	5.37e-06	0.000148	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	5.27e-06	0.000145	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	5.23e-06	0.000144	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	5.11e-06	0.000141	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	5.11e-06	0.000141	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	4.99e-06	0.000138	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	4.83e-06	0.000133	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	4.83e-06	0.000133	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	4.62e-06	0.000128	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTEN—ovarian cancer	4.55e-06	0.000126	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	4.44e-06	0.000122	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	4.42e-06	0.000122	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	4.29e-06	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	4.1e-06	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	4.08e-06	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	3.93e-06	0.000108	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3.62e-06	0.0001	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.21e-06	8.87e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKT1—ovarian cancer	2.62e-06	7.25e-05	CbGpPWpGaD
